Parvoduk

RSS

live attenuated Muscovy duck parvovirus

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Parvoduk has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

This EPAR was last updated on 15/04/2019

Authorisation details

Product details
Name
Parvoduk
Agency product number
EMEA/V/C/002740
Active substance
live attenuated Muscovy duck parvovirus
International non-proprietary name (INN) or common name
live attenuated Muscovy duck parvovirus
Species
Ducks
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI01BD03
Publication details
Marketing-authorisation holder
Merial
Revision
2
Date of issue of marketing authorisation valid throughout the European Union
11/04/2014
Contact address

29 Avenue Tony Garnier
69007 Lyon
France

Product information

09/01/2019 Parvoduk - EMEA/V/C/002740 - R/0006

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Immunologicals for ducks
  • live viral vaccines against duck parvovirus

Therapeutic indication

Active immunisation of ducks to prevent mortality1 and to reduce weight loss and lesions of duck parvovirosis and Derzsy's disease.


1In absence of maternally derived antibodies.

Assessment history

How useful was this page?

Add your rating